R B Moss

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. doi request reprint The use of biological agents for the treatment of fungal asthma and allergic bronchopulmonary aspergillosis
    Richard B Moss
    Department of Pediatrics, Stanford University School of Medicine, Stanford, California, USA
    Ann N Y Acad Sci 1272:49-57. 2012
  2. pmc Specific antibodies to recombinant allergens of Aspergillus fumigatus in cystic fibrosis patients with ABPA
    Viswanath P Kurup
    Allergy Immunology Division, Medical College of Wisconsin and Research Service, V A Medical Center, 5000 West National Avenue, Milwaukee, WI 53295, USA
    Clin Mol Allergy 4:11. 2006
  3. ncbi request reprint Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial
    Richard B Moss
    Department of Pediatrics, Stanford University, Stanford, CA 94305, and Division of Respiratory Diseases, Children s Hospital Boston, MA 02115, USA
    Hum Gene Ther 18:726-32. 2007
  4. ncbi request reprint Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease
    Richard B Moss
    Department of Pediatrics, Stanford University Medical Center, Palo Alto, California 94304 5786, USA
    Pediatr Pulmonol 39:209-18. 2005
  5. ncbi request reprint Allergic bronchopulmonary aspergillosis
    Richard B Moss
    Department of Pediatrics, Stanford University, Palo Alto, CA, USA
    Clin Rev Allergy Immunol 23:87-104. 2002
  6. ncbi request reprint Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis
    Richard B Moss
    Department of Pediatrics, Stanford University Medical Center, Palo Alto, CA 94304 5786, USA
    Chest 121:55-63. 2002
  7. ncbi request reprint Administration of aerosolized antibiotics in cystic fibrosis patients
    R B Moss
    Department of Pediatric Pulmonary Medicine, Stanford University Medical Center, Palo Alto, CA 94304 5786, USA
    Chest 120:107S-113S. 2001
  8. ncbi request reprint Pathophysiology and immunology of allergic bronchopulmonary aspergillosis
    R B Moss
    Department of Pediatrics, Division of Pulmonary Medicine, Stanford University, Palo Alto, CA 94304 5786, USA
    Med Mycol 43:S203-6. 2005
  9. doi request reprint Allergic bronchopulmonary aspergillosis and Aspergillus infection in cystic fibrosis
    Richard B Moss
    Department of Pediatrics, Stanford University, Palo Alto, CA 94304, USA
    Curr Opin Pulm Med 16:598-603. 2010
  10. pmc Cytokine dysregulation in activated cystic fibrosis (CF) peripheral lymphocytes
    R B Moss
    Department of Paediatrics, Stanford University School of Medicine, Palo Alto, CA 94304 5786, USA
    Clin Exp Immunol 120:518-25. 2000

Detail Information

Publications32

  1. doi request reprint The use of biological agents for the treatment of fungal asthma and allergic bronchopulmonary aspergillosis
    Richard B Moss
    Department of Pediatrics, Stanford University School of Medicine, Stanford, California, USA
    Ann N Y Acad Sci 1272:49-57. 2012
    ..Controlled trials of Th2-inhibiting biologicals in patients with ABPA and severe asthma with fungal sensitization appear warranted...
  2. pmc Specific antibodies to recombinant allergens of Aspergillus fumigatus in cystic fibrosis patients with ABPA
    Viswanath P Kurup
    Allergy Immunology Division, Medical College of Wisconsin and Research Service, V A Medical Center, 5000 West National Avenue, Milwaukee, WI 53295, USA
    Clin Mol Allergy 4:11. 2006
    ..However, this is not true with cystic fibrosis patients where the prevalence of ABPA is fairly high and the morbidity and mortality are significant...
  3. ncbi request reprint Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial
    Richard B Moss
    Department of Pediatrics, Stanford University, Stanford, CA 94305, and Division of Respiratory Diseases, Children s Hospital Boston, MA 02115, USA
    Hum Gene Ther 18:726-32. 2007
    ..Because gene transfer is the simplest, most basic way to correct the underlying genetic defect that leads to disease in CF, further research is warranted to develop an effective gene transfer agent for the treatment of CF...
  4. ncbi request reprint Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease
    Richard B Moss
    Department of Pediatrics, Stanford University Medical Center, Palo Alto, California 94304 5786, USA
    Pediatr Pulmonol 39:209-18. 2005
    ..Aerosolized IFN-gamma1b did not improve pulmonary function, reduce sputum bacterial density, or affect inflammatory sputum markers in patients with mild-moderate lung disease...
  5. ncbi request reprint Allergic bronchopulmonary aspergillosis
    Richard B Moss
    Department of Pediatrics, Stanford University, Palo Alto, CA, USA
    Clin Rev Allergy Immunol 23:87-104. 2002
    ..Monitoring of clinical, radiographic and laboratory responses (especially total serum IgE) is essential...
  6. ncbi request reprint Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis
    Richard B Moss
    Department of Pediatrics, Stanford University Medical Center, Palo Alto, CA 94304 5786, USA
    Chest 121:55-63. 2002
    ..To determine the effect of long-term suppression of Pseudomonas aeruginosa on lung function and other clinical end points in adolescent patients with cystic fibrosis (CF)...
  7. ncbi request reprint Administration of aerosolized antibiotics in cystic fibrosis patients
    R B Moss
    Department of Pediatric Pulmonary Medicine, Stanford University Medical Center, Palo Alto, CA 94304 5786, USA
    Chest 120:107S-113S. 2001
    ..Antibiotic susceptibility of the bacterial isolates did not predict clinical response. TSI was safe, well-tolerated, and effective for long-term treatment (96 weeks) of P aeruginosa colonization and infection in CF patients...
  8. ncbi request reprint Pathophysiology and immunology of allergic bronchopulmonary aspergillosis
    R B Moss
    Department of Pediatrics, Division of Pulmonary Medicine, Stanford University, Palo Alto, CA 94304 5786, USA
    Med Mycol 43:S203-6. 2005
    ..It is treated with systemic glucocorticoids and azoles. Monitoring clinical, radiographic and serologic responses (especially total IgE) is essential for successful management...
  9. doi request reprint Allergic bronchopulmonary aspergillosis and Aspergillus infection in cystic fibrosis
    Richard B Moss
    Department of Pediatrics, Stanford University, Palo Alto, CA 94304, USA
    Curr Opin Pulm Med 16:598-603. 2010
    ..fumigatus airways infection and A. fumigatus allergy without allergic bronchopulmonary aspergillosis (ABPA)...
  10. pmc Cytokine dysregulation in activated cystic fibrosis (CF) peripheral lymphocytes
    R B Moss
    Department of Paediatrics, Stanford University School of Medicine, Palo Alto, CA 94304 5786, USA
    Clin Exp Immunol 120:518-25. 2000
    ..These findings extend defects described in respiratory epithelial cells to circulating immunoregulatory cells, suggesting a link between CF genotype and cytokine dysregulation...
  11. ncbi request reprint Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial
    Richard B Moss
    Department of Pediatrics, Stanford University, Stanford, CA, USA
    Chest 125:509-21. 2004
    ....
  12. ncbi request reprint Sensitization to aztreonam and cross-reactivity with other beta-lactam antibiotics in high-risk patients with cystic fibrosis
    R B Moss
    Department of Pediatrics, Stanford University School of Medicine, Calif
    J Allergy Clin Immunol 87:78-88. 1991
    ..However, caution should be exercised with aztreonam in BLA-allergic patients with CF in light of 5% preexisting ST cross-reactivity and 20% sensitization rates found in this study...
  13. ncbi request reprint Maxillary sinusitis as a surrogate model for CF gene therapy clinical trials in patients with antrostomies
    J A Wagner
    Department of Molecular Pharmacology, Stanford University School of Medicine, CA 94305 5332, USA
    J Gene Med 1:13-21. 1999
    ..Using CF sinusitis as a surrogate model for testing clinical efficacy of new treatments is attractive because CF upper respiratory disease is similar to the lower respiratory disease with respect to electrophysiology and microbiology...
  14. pmc Diagnostic testing by CFTR gene mutation analysis in a large group of Hispanics: novel mutations and assessment of a population-specific mutation spectrum
    Iris Schrijver
    Department of Pathology, L235, Stanford University Medical Center, Stanford, CA 94305, USA
    J Mol Diagn 7:289-99. 2005
    ..These results underscore the disparity in mutation identification between Caucasians and Hispanics and show utility for comprehensive diagnostic CFTR mutation analysis in this population...
  15. ncbi request reprint Dornase alfa reduces air trapping in children with mild cystic fibrosis lung disease: a quantitative analysis
    Terry E Robinson
    Department of Pediatrics Pulmonary, Pediatric Pulmonary Division, Stanford University Medical Center, 701 Welch Rd, Whelan Building, 3328, Palo Alto, CA 94305 5786, USA
    Chest 128:2327-35. 2005
    ....
  16. ncbi request reprint Allergic bronchopulmonary aspergillosis in cystic fibrosis--state of the art: Cystic Fibrosis Foundation Consensus Conference
    David A Stevens
    Department of Medicine, Santa Clara Valley Medical Center, Stanford University Medical School, San Jose, California 95128 2699, USA
    Clin Infect Dis 37:S225-64. 2003
    ..Diagnostic criteria that could provide a framework for monitoring were adopted, and helpful imaging features were identified. New possibilities in therapy produced plans for managing diverse clinical presentations...
  17. pmc Profound functional and signaling changes in viable inflammatory neutrophils homing to cystic fibrosis airways
    Rabindra Tirouvanziam
    Departments of Pediatrics, Genetics, and Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA
    Proc Natl Acad Sci U S A 105:4335-9. 2008
    ..Thus, we identified a subset of neutrophils within CF airways with a viable but dysfunctional phenotype. This subset provides a possible therapeutic target and indicates a need to revisit current paradigms of CF airway disease...
  18. ncbi request reprint Composite spirometric-computed tomography outcome measure in early cystic fibrosis lung disease
    Terry E Robinson
    Pediatric Pulmonary Division, Stanford University Medical Center, 701 Welch Road, Whelan Building 3328, Palo Alto, CA 94304 5786
    Am J Respir Crit Care Med 168:588-93. 2003
    ....
  19. ncbi request reprint A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies
    John A Wagner
    Department of Molecular Pharmacology, Stanford CCSR Building, Stanford, CA 94305 5174, USA
    Hum Gene Ther 13:1349-59. 2002
    ..In summary, this Phase II trial confirms the safety of tgAAVCF but provides little support of its efficacy in the within-patient controlled sinus study. Various potentially confounding factors are discussed...
  20. doi request reprint Cystic fibrosis HRCT scores correlate strongly with Pseudomonas infection
    Terry E Robinson
    Center of Excellence for Pediatric Cystic Fibrosis and Pulmonary Diseases, Stanford University Medical Center, Palo Alto, California 94305 5715, USA
    Pediatr Pulmonol 44:1107-17. 2009
    ....
  21. doi request reprint Safety, tolerability, and efficacy of high-frequency chest wall oscillation in pediatric patients with cerebral palsy and neuromuscular diseases: an exploratory randomized controlled trial
    Nanci Yuan
    Department of Pediatrics, Division of Pulmonology, Stanford University, Palo Alto, California 94304, USA
    J Child Neurol 25:815-21. 2010
    ..Our data suggest safety, tolerability, and better compliance with high-frequency chest wall oscillation. Improvement in airway clearance may help prevent hospitalizations. Larger controlled trials are required to confirm these results...
  22. pmc High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis
    Rabindra Tirouvanziam
    Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA
    Proc Natl Acad Sci U S A 103:4628-33. 2006
    ..032). Thus, high-dose oral N-acetylcysteine has the potential to counter the intertwined redox and inflammatory imbalances in CF...
  23. pmc Reduced IL-10 secretion by CD4+ T lymphocytes expressing mutant cystic fibrosis transmembrane conductance regulator (CFTR)
    R B Moss
    Department of Pediatrics, Stanford University School of Medicine, CA 94305 5119, USA
    Clin Exp Immunol 106:374-88. 1996
    ..It is possible that disruption of IL-10-mediated anti-inflammatory homeostasis may contribute to early onset sustained inflammation in CF airways...
  24. ncbi request reprint Deficiency of IgG4 in children: association of isolated IgG4 deficiency with recurrent respiratory tract infection
    R B Moss
    Allergy Pulmonary Division, Lucille Salter Packard Children s Hospital, Standford, Palo Alto, CA 94304
    J Pediatr 120:16-21. 1992
    ..This association suggests a physiologic defense role for mucosal IgG4...
  25. ncbi request reprint Spirometer-triggered high-resolution computed tomography and pulmonary function measurements during an acute exacerbation in patients with cystic fibrosis
    T E Robinson
    Division of Pediatric Pulmonology, Stanford University Medical Center, Palo Alto 94304-5786, California, USA
    J Pediatr 138:553-9. 2001
    ..Total and reversible HRCT scores and percent predicted SVC, FEV1, and FVC were the most sensitive to change. The greatest change was seen in the mucus plugging subcomponent HRCT score...
  26. ncbi request reprint Comprehensive mutation screening in a cystic fibrosis center
    J J Wine
    Cystic Fibrosis Research Laboratory, Stanford University, Stanford, California, USA
    Pediatrics 107:280-6. 2001
    ..We discuss 5 possible explanations that could account for the few remaining undetected mutations...
  27. pmc Expression of perforin on HIV-1-specific CD8+ lymphocytes after immunization with a gp120-depleted, whole-killed HIV-1 immunogen
    R B Moss
    The Immune Response Corporation, Carlsbad, CA, USA
    Clin Exp Immunol 124:248-54. 2001
    ..The induction of such responses with immunization may have direct antiviral consequences and is being studied in ongoing clinical trials...
  28. ncbi request reprint Advances against aspergillosis
    William J Steinbach
    Division of Pediatric Infectious Diseases, Department of Pediatrics, Duke University, Durham, North Carolina, USA
    Clin Infect Dis 37:S155-6. 2003
  29. pmc Activation of critical, host-induced, metabolic and stress pathways marks neutrophil entry into cystic fibrosis lungs
    Megha Makam
    Department of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305, USA
    Proc Natl Acad Sci U S A 106:5779-83. 2009
    ..Taken together, our data demonstrate an early and sustained activation of host-responsive metabolic and stress pathways upon neutrophil entry into CF airways, suggesting potential targets for therapeutic modulation...
  30. pmc Fully automated system for three-dimensional bronchial morphology analysis using volumetric multidetector computed tomography of the chest
    Raman Venkatraman
    Department of Pediatric Pulmonology, Stanford University School of Medicine, Stanford, CA 94305, USA
    J Digit Imaging 19:132-9. 2006
    ....
  31. ncbi request reprint Sputum cathelicidin, urokinase plasminogen activation system components, and cytokines discriminate cystic fibrosis, COPD, and asthma inflammation
    Wei Xiao
    Department of Medicine, Shandong University, Jinan, People s Republic of China
    Chest 128:2316-26. 2005
    ..We investigated several components of innate immunity in induced sputum of patients with cystic fibrosis (CF), COPD, and asthma, and healthy control subjects...
  32. ncbi request reprint Quantitative air-trapping analysis in children with mild cystic fibrosis lung disease
    Anne Sophie Bonnel
    Division of Pediatric Respirology, University Hospital, Rouen, France
    Pediatr Pulmonol 38:396-405. 2004
    ..Pulmonary density measurements and % AT better discriminated differences between groups than PFTs. Measurements made on expiratory scans near FRC showed significantly higher values for AT than those made near RV...